Core Insights - The article discusses the impact of multilingualism on healthy aging, highlighting that speaking multiple languages may slow down cognitive decline and reduce the likelihood of accelerated aging by half compared to monolingual individuals [2][3][6]. Group 1: Research Findings - A study involving over 86,000 participants aged 51-90 from 27 European countries found that multilingual individuals have a significantly lower risk of accelerated aging [3][7]. - The research established a biobehavioral age gap, which measures the difference between actual age and predicted age based on various health and lifestyle factors, indicating the speed of aging [6][7]. - The study revealed a dose-dependent effect of multilingualism, where the more languages a person speaks, the more pronounced the delay in aging [7][9]. Group 2: Implications for Public Health - The findings suggest that promoting multilingualism could be a viable public health strategy to support healthy aging at the population level [3][9]. - The research addresses a long-standing gap in aging studies by using a large and diverse sample, thus controlling for common confounding factors such as immigration status and wealth [9].

Core Insights - The article discusses the role of Adipogenin (Adig) in lipid metabolism, highlighting its interaction with seipin to form a dodecameric complex that promotes lipid droplet development [2][3][11]. Molecular Function - Adig is a microprotein composed of 80 amino acids, highly expressed in adipose tissue and fatty liver, and is linked to leptin levels in the blood, indicating its significance in energy metabolism [2]. - The study published in Science reveals that Adig interacts with seipin to form a stable complex, which is crucial for lipid droplet formation and expansion [3][11]. Structural Insights - The seipin-Adig complex provides a structural platform for lipid droplet formation, with Adig modulating the conformation of seipin to regulate lipid storage capacity, resulting in fewer but larger lipid droplets [7][10]. - Cryo-electron microscopy analysis identified two oligomeric forms: a seipin eleven-mer and a seipin-Adig twelve-mer, with resolutions of approximately 3.2 Å and 3.0 Å, respectively [8]. Physiological Impact - The presence of the seipin-Adig complex alters triglyceride flow in the endoplasmic reticulum, leading to the formation of larger lipid droplets [10]. - In mouse models, overexpression of Adig in adipocytes promotes lipid droplet enlargement and adipose tissue expansion, while its absence reduces the number of seipin complexes and impairs triglyceride accumulation in brown adipose tissue [10][11]. Conclusion - The research establishes Adig as a key auxiliary factor that regulates seipin's function and lipid storage in adipose tissue, providing new potential intervention targets for diseases related to lipid metabolism disorders [11].

Core Viewpoint - Obesity is a complex disease that significantly contributes to metabolic disorders and poses a heavy burden on healthcare systems. Current interventions have limited long-term efficacy, highlighting the need for a deeper understanding of the mechanisms behind obesity development [2]. Group 1: Mechanisms of Obesity - The primary cause of obesity is energy imbalance, where energy intake exceeds energy expenditure over time. The energy homeostasis is regulated by the brain-peripheral organ interaction, particularly through the gut-brain axis and the fat-brain axis [2]. - Research on the gut-brain axis has made significant progress, especially in targeting incretin pathways, while the core mechanisms of the fat-brain axis remain to be fully understood [2]. Group 2: Leptin Resistance - Leptin, a key feedback signal from adipose tissue, regulates energy balance by inhibiting food intake and promoting energy expenditure. However, obesity often leads to leptin resistance, disrupting the communication between adipose tissue and the brain [3][4]. - A recent study published in Cell Metabolism reveals a new mechanism driving central leptin resistance, identifying extracellular vesicles (EVs) derived from adipose tissue as crucial regulators of central leptin sensitivity [4][10]. Group 3: Role of Extracellular Vesicles - The study demonstrates that inhibiting adipose EV production in animal models leads to significant weight gain and increased body fat due to increased food intake and decreased energy expenditure [5]. - Only EVs from healthy mice effectively reduced weight and improved energy imbalance in obese mice, indicating the importance of healthy adipose EVs in maintaining energy homeostasis [5][6]. Group 4: Mechanisms of Action - The weight loss effect of adipose EVs relies on an intact leptin signaling pathway, as they do not induce weight loss in leptin-deficient mice [6]. - Adipose EVs can cross the blood-brain barrier and specifically target neurons expressing leptin receptors, enhancing central leptin sensitivity and maintaining energy balance [6][8]. Group 5: miRNA and Targeting Mechanisms - miRNA within adipose EVs are identified as key components mediating the effects on central leptin sensitivity. The study categorizes miRNAs into leptin-sensitizing and leptin-desensitizing types, with the former being crucial for preventing central leptin resistance [7][10]. - The research also identifies specific membrane proteins on adipose EVs that facilitate brain targeting, leading to the development of engineered EVs for delivering leptin-sensitizing miRNAs to the brain [8][10]. Group 6: Implications for Treatment - This research shifts the paradigm of leptin resistance from a central brain-focused approach to an inter-organ communication framework, opening new avenues for innovative obesity therapies targeting the fat-brain axis [10][11].

Core Insights - The article discusses the significance of tandem perovskite LEDs in the new display technology sector, highlighting their potential to enhance efficiency and longevity compared to single-layer devices [2][6]. Group 1: Technology Overview - Light Emitting Diodes (LEDs) are identified as a key technology in the new display field, representing emerging industries and new productive forces [2]. - Tandem LEDs improve efficiency and lifespan by stacking multiple light-emitting units vertically [2]. Group 2: Research Breakthrough - A recent study published in Nature by researchers from Nanjing University of Technology achieved a peak external quantum efficiency of 45.5% and an average peak efficiency of 40.9%, setting a new record for tandem perovskite LEDs [3][6]. - The research utilized interlayer photon recycling to develop high-performance tandem LEDs, achieving a low operating voltage of 3.2 V and a long half-life of 64 hours at an initial brightness of 70 W·Sr⁻¹·m⁻² [6]. Group 3: Implications and Future Directions - The findings signify a major breakthrough in achieving high-performance multi-color LEDs through perovskite stacking technology [7]. - The advancements in perovskite LEDs are paving the way for potential industrial applications, with previous research also indicating a significant increase in external quantum efficiency, surpassing 30% [8].

Core Insights - Iambic Therapeutics has successfully completed an oversubscribed financing round exceeding $100 million, aimed at accelerating clinical development of multiple AI-driven therapeutic pipelines and seeking further commercial collaborations [3][5]. Financing Highlights - The financing attracted a prestigious lineup of investors, including Abingworth, Illumina Ventures, Regeneron Ventures, Sequoia, and Qatar Investment Authority, indicating strong confidence in Iambic's unique technology platform and R&D strategy [5]. Technical Developments - Iambic recently established a significant collaboration with Jazz Therapeutics to jointly research IAM1363, a small molecule HER2 tyrosine kinase inhibitor, in combination with Jazz's HER2-targeted bispecific antibody Ziihera, targeting difficult-to-treat HER2-positive breast cancer [8]. - The collaboration was spurred by promising early clinical data for IAM1363, which demonstrated anti-tumor activity across various cancers, particularly in patients resistant to existing HER2-targeted therapies [8]. AI Empowerment in Drug Development - Iambic's core competitive advantage lies in its AI drug discovery platform, which streamlines the traditionally lengthy and costly drug development process, exemplified by IAM1363, which was designed to overcome limitations of current HER2-targeted therapies [10]. Future Outlook - Iambic's growth trajectory reflects the broader AI pharmaceutical landscape, having raised $53 million in Series A funding in 2021 and $100 million in Series B funding in 2023, alongside collaborations with companies like Revolution Medicines, indicating its AI platform's potential for commercial value [12]. - With new funding and deepening collaborations, Iambic is transitioning from a technology validation-focused AI platform to a biopharmaceutical company with multiple clinical pipelines and strong commercialization potential [12]. Rapid Prediction and Intelligent Design - Utilizing its advanced protein structure prediction model NeuralPLexer, Iambic can quickly and accurately predict drug molecule interactions with target proteins, significantly shortening preclinical research timelines [14]. - Based on these predictions, the company can design superior and safer drug candidates, enhancing the efficiency of the drug development process [14].

Core Insights - Eli Lilly and Insilico Medicine announced a collaboration worth over $100 million to leverage AI for drug discovery [3][5] - The partnership aims to combine Eli Lilly's expertise in drug development with Insilico's Pharma.AI platform to discover and advance innovative therapies [3][5] Group 1: Collaboration Details - The collaboration includes upfront payments, research milestone payments, and royalties from future drug sales, with Insilico potentially earning over $100 million [3] - Eli Lilly has previously collaborated with Insilico, utilizing the Pharma.AI platform, indicating satisfaction with past results [5] Group 2: Insilico Medicine's Capabilities - Insilico Medicine has significantly improved early drug development efficiency, reducing the typical 3-6 year timeline to an average of 12-18 months for candidate nomination [5] - The company has nominated 20 preclinical candidates from 2021 to 2024, showcasing its accelerated development process [5] Group 3: Industry Interest - Insilico Medicine has attracted interest from other major pharmaceutical companies, including Sanofi, Pfizer, Menarini Group, and Boehringer Ingelheim [6] - Eli Lilly is actively building its AI capabilities, recently partnering with NVIDIA to create a new supercomputer for AI-driven research [6]

排版丨水成文 2025 年 11 月 10 日，国际顶尖学术期刊 Nature 加速上线了两篇研究论文 【1、2】 ， 苏州大学 为两篇论 文的第一单位，苏州大学 张晓宏 教授为两篇论文的主要通讯作者。 撰文丨王聪 编辑丨王多鱼 第一篇论文题为： Flexible perovskite/silicon tandem solar cells with 33.6% efficiency （ 效率达 33.6% 的柔性钙钛矿/硅叠层太阳能电池 ） 。苏州大学 张晓宏 教授 、 杨新波 教授及 阿卜杜拉国王科技 大学 Stefaan De Wolf 为论文共同通讯作者，苏州大学 Wang Shibo、Li Wenhao、Yu Cao、Shi Wei 及 北京工业大学 Kang Qian 为论文共同第一作者。 柔性太阳能电池 在特定应用领域具有变革性潜力，但在同时实现高功率转换效率（PCE）、极端机械韧性 和运行稳定性方面仍面临根本性挑战。 该研究展示了一种认证效率高达 33.6% 的 柔性钙钛矿/晶体硅叠层太阳能电池 ，其开路电压 （ V oc ） 创纪录地达到了 2.015 V，性能可与刚性器件媲美。该柔性叠层器件 ...

Core Viewpoint - The recent randomized clinical trial published in JAMA indicates that consuming caffeinated coffee may significantly reduce the recurrence rate of atrial fibrillation (AF) in patients, contrary to traditional beliefs that it may exacerbate the condition [2][4][7]. Group 1: Study Overview - The study involved 200 participants aged around 69 years, with 71% being male, who were either current or past coffee drinkers and had a history of persistent AF or atrial flutter [5]. - Participants were randomly assigned to either a caffeinated coffee group or a coffee abstinence group for a duration of 6 months, with the primary endpoint being the recurrence of AF or atrial flutter [4][5]. Group 2: Findings - The recurrence rate of AF or atrial flutter in the caffeinated coffee group was 47%, significantly lower than the 64% in the abstinence group, indicating a 39% reduction in recurrence risk [5]. - The study found no significant difference in adverse events between the two groups, suggesting that moderate coffee consumption is safe for AF patients [5][7]. Group 3: Implications - The research suggests that caffeine may act as a diuretic, potentially lowering blood pressure and reducing AF risk, while also having anti-inflammatory effects [7]. - The findings challenge the traditional view that coffee consumption is harmful for AF patients, indicating that moderate intake may actually provide protective benefits [7].

Core Viewpoint - The article discusses the seasonal influenza epidemic and the interactions between various respiratory viruses, highlighting the importance of understanding viral co-infections and their implications for public health and treatment strategies [2][3]. Summary by Sections Influenza Season and Predictions - The seasonal influenza typically peaks in China between mid-December and early January, with an expected rise in cases this year [2]. Viral Co-infections and Their Effects - Respiratory viruses such as influenza, respiratory syncytial virus (RSV), rhinovirus, and others can co-infect hosts, leading to varying clinical outcomes, either exacerbating or alleviating symptoms [3][4]. - Co-infections can result in two distinct outcomes: either reducing symptoms or worsening them, as demonstrated in mouse models [4][6]. Mechanisms of Viral Interference - Viral interference can be classified into positive and negative interactions. Positive interactions can worsen conditions, while negative interactions can inhibit viral infections [3][5]. - The concept of viral interference was introduced in the 1960s, with interferon responses being a key mechanism in these interactions [5][10]. Implications for Treatment and Research - Understanding the mechanisms of viral interference is crucial for developing treatment, prevention, and diagnostic strategies for infectious diseases [10]. - The article emphasizes the role of viral surface proteins in these interactions, suggesting that recombinant viral antigens and antibodies are essential for research [10]. Company Solutions - Yiqiao Shenzhou provides a comprehensive range of viral reagents and solutions for infectious disease research, supporting global efforts in basic research, therapeutic antibody development, drug research, diagnostics, and vaccine development [12][13].

Core Insights - The article discusses the relationship between cerebrospinal fluid (CSF) circulation disorders and various neurological diseases, emphasizing the potential of low-intensity ultrasound treatment to clear harmful debris caused by hemorrhagic stroke, which could lead to improved outcomes without invasive procedures [1][2][5]. Group 1: Research Findings - The study published by Stanford University researchers demonstrates that low-intensity ultrasound can effectively clear harmful debris and inflammation resulting from hemorrhagic stroke [2][5]. - In preclinical models, ultrasound treatment was shown to remove over 50% of red blood cells from the CSF and brain interstitium, facilitating waste clearance through meningeal lymphatics to deep cervical lymph nodes [5][7]. - The ultrasound treatment group exhibited reduced brain inflammation and neuronal damage compared to untreated mice, with improved survival rates and better performance in behavioral tests [5][7]. Group 2: Treatment Implications - The ultrasound treatment method aligns with FDA safety guidelines for ultrasound exposure, and clinical trials are planned to further validate its effectiveness [7]. - If successful in clinical trials, this non-invasive ultrasound therapy could not only benefit hemorrhagic stroke patients but also offer therapeutic advantages for other neurological diseases associated with toxic debris accumulation [7].